摘要
目的分析慢性心力衰竭(简称心衰)患者应用沙库巴曲缬沙坦钠片治疗的效果及安全性。方法随机将2021年1月—2022年1月北京市房山区中医医院的80例慢性心衰患者分为对照组(40例)和观察组(40例),分别接受常规治疗和沙库巴曲缬沙坦钠片治疗,对比两组患者临床效果。结果观察组总有效率为97.50%,高于对照组的75.00%,差异有统计学意义(χ^(2)=8.537,P<0.05);观察组治疗后LVEDD为(47.39±4.32)mm,LVESD为(40.47±3.40)mm,LVEF为(48.63±5.49)%,优于对照组,差异有统计学意义(t=10.189、7.778、10.021,P<0.05);观察组治疗后舒张压为(76.22±2.24)mmHg,收缩压为(122.23±2.04)mmHg,优于对照组,差异有统计学意义(t=11.298、19.204,P<0.05);观察组治疗后NT-proBNP为(435.91±59.13)pg/mL,6 min步行距离为(309.70±34.27)m,优于对照组,差异有统计学意义(t=7.217、5.842,P<0.05),观察组治疗后hs-CRP为(3.21±1.40)mg/L,TNF-α为(13.48±3.56)ng/L,优于对照组,差异有统计学意义(P<0.05);两组不良反应发生率分别为7.50%、10.00%,差异无统计学意义(P>0.05)。结论慢性心衰采用沙库巴曲缬沙坦钠片治疗具有良好效果,安全性高,值得临床广泛推广及应用。
Objective To analyze the efficacy and safety of sacubitril valsartan sodium tablets in the treatment of chronic heart failure(referred to as heart failure).Methods A total of eighty patients with chronic heart failure in Beijing Fangshan District Hospital of Traditional Chinese Medicine from January 2021 to January 2022 were randomly divided into control group(40 cases)and observation group(40 cases).The clinical effects of conventional treatment and sacubitril valsartan sodium tablets were compared between the two groups.Results The total effective rate was 97.50%in the observation group,higher than 75.00%in the control group,and the difference was statistically significant(χ^(2)=8.537,P<0.05).LVEDD,LVESD and LVEF were(47.39±4.32)mm,(40.47±3.40)mm and(48.63±5.49)%in the observation group after treatment,which were better than those in the control group,and the difference was statistically significant(t=10.189,7.778,10.021,P<0.05).After treatment,the diastolic blood pressure and systolic blood pressure of the observation group were(76.22±2.24)mmHg and(122.23±2.04)mmHg respectively,which were better than those in the control group,and the difference was statistically significant(t=11.298,19.204,P<0.05).After treatment,the NT-proBNP of the observation group was(435.91±59.13)pg/mL,and the 6-min walking distance was(309.70±34.27)m,which were better than those of the control group,and the difference was statistically significant(t=7.217,5.842,P<0.05).After treatment,hs-CRP was(3.21±1.40)mg/L and TNF-αwas(13.48±3.56)ng/L in observation group,which was better than those of the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions in 2 groups(7.50%and 10.00%)(P>0.05).Conclusion The treatment of chronic heart failure with sacubitril valsartan sodium tablets has good effect and high safety,and is worthy of widespread clinical promotion and application.
作者
王颜波
臧冬梅
WANG Yanbo;ZANG Dongmei(Department of Cardiovascular Diseases,Fangshan District Hospital of Traditional Chinese Medicine,Beijing,102400 China)
出处
《中外医疗》
2023年第23期1-5,共5页
China & Foreign Medical Treatment
基金
2020年新教师启动基金项目(2020-BUCMXJKY-012)。
关键词
慢性心衰
沙库巴曲缬沙坦钠片
心功能
炎症反应
安全性
Chronic heart failure
Sacubitril valsartan sodium tablets
Heart function
Inflammatory response
Safety
作者简介
王颜波(1980-),女,本科,主治医师,研究方向为心血管、高血压;通信作者:臧冬梅(1981-),女,本科,副主任医师,研究方向为中西医结合防治心血管病科,E-mail:zangyisheng0763@163.com。
